Nasal Virus-Induced Molecule Analysis for Respiratory Infection Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic strategies for respiratory illnesses are time-consuming and costly, often requiring multiple tests for distinct viruses, and may lead to inappropriate antibiotic use due to undetermined viral or bacterial causes, necessitating a more efficient and reliable method to differentiate between viral and bacterial infections.
Innovation Solution
A method involving the analysis of nasal virus-induced molecules (Na-VIMs) in viral transport medium samples, using mRNA or protein measurements, to determine the presence of respiratory viral infections by normalizing levels against housekeeping genes and comparing them to reference levels, facilitating rapid diagnosis and appropriate treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If multiple virus-specific tests are performed to identify the cause of respiratory illness, then diagnostic accuracy is improved, but testing time and cost increase significantly
Solution Approach 1:
The invention segments the diagnostic approach by dividing respiratory infections into two distinct categories: viral and bacterial. Instead of testing for multiple individual viruses, the method uses a single test that detects viral infection markers (such as interferon-stimulated genes) to differentiate viral from bacterial causes, thereby reducing testing time while maintaining diagnostic accuracy for determining the appropriate treatment pathway.
2Measurement precision
If multiple virus-specific tests are performed to identify the cause of respiratory illness, then diagnostic accuracy is improved, but testing cost increases
Solution Approach 1:
The diagnostic strategy is segmented into a cost-effective two-step approach: first, a single viral infection test using viral transport medium analysis; second, if needed, targeted bacterial testing. This segmentation eliminates the need for expensive panels of multiple virus-specific tests while maintaining the ability to accurately determine whether antiviral or antibiotic treatment is appropriate.
3Reliability
If antibiotics are prescribed without confirmed bacterial infection, then treatment coverage is improved, but antibiotic resistance and harmful side effects increase
Solution Approach 1:
The invention introduces an intermediary diagnostic test (detection of viral infection markers in viral transport medium) that acts as a mediator between clinical presentation and treatment decision. This intermediary test provides objective evidence to guide whether antibiotics are appropriate, reducing unnecessary antibiotic prescriptions while ensuring adequate coverage when bacterial infection is confirmed, thereby addressing both treatment coverage and antibiotic resistance concerns.
4Productivity
If a simple rapid test is used to detect respiratory infection, then testing time is reduced, but diagnostic precision may be compromised
Solution Approach 1:
The invention extracts and measures specific viral infection markers (such as interferon-stimulated genes like IFIT1, IFIT2, IFIT3, OASL, OAS1, OAS2, OAS3, ISG15, IFIH1, IFI44, DDX58, DDX60, HERC5, MX1, MX2, IFITM1, RSAD2, IFI44L, IFI27, DHX58, CXCL10, CX3CL1, CXCL8, CXCL11, CXCL1, IL36G, IFNL1, CXCL9, CCL20, IFNL2, CXCL2, TNF, CXCL3, or CCL22) directly from the viral transport medium. This extraction of specific biomarkers enables a simple rapid test format while maintaining high diagnostic precision through targeted measurement of viral response indicators.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables rapid and accurate differentiation of respiratory viral infections, reducing inappropriate antibiotic use and improving patient care by providing a practical and reliable test for guiding medical decisions.
Implementation Method 1
In various embodiments, the mRNA is measured by reverse transcription-qPCR.
Implementation Method 2
normalizing the level of the at least one nasal virus-induced molecule to the level of the housekeeping gene to determine a normalized level of the at least one nasal virus-induced molecule
Data Source
AI summary
The present disclosure concerns methods of detecting viral respiratory infections by analyzing biomarkers in a viral transport medium sample. In various embodiments the biomarkers are assessed by measuring mRNA or protein. In certain embodiments the biomarkers are nasal-virus induced molecules.